According to a new report Global Companion Diagnostics Market, published by KBV research, The Global Companion Diagnostics Market size is expected to reach $6.5 billion by 2025, rising at a market growth of 19.9% CAGR during the forecast period.
The Polymerase Chain Reaction (PCR) market dominated the Global Companion Diagnostics Market by Technology in 2018, growing at a CAGR of 20.3% during the forecast period. The Immunohistochemistry market is expected to witness a CAGR of 19.1% during (2019 - 2025).
The Oncology market dominated the Global Companion Diagnostics Market by Indication in 2018, growing at a CAGR of 21.1 % during the forecast period. The Neurology market is expected to witness a CAGR of 18.3% during (2019 - 2025).
The North America market dominated the Global Lung Cancer Companion Diagnostics by Region in 2018, growing at a CAGR of 21.7 % during the forecast period. The Europe market is expected to witness a CAGR of 19.9% during (2019 - 2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 23.5% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/companion-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
By Technology
By Indication
By Cancer Type
By Geography
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
